Hemophagocytic lymphohistiocytosis (HLH) is a severe and potentially lethal disorder associated with excessive inflammation and unrestrained immune activation [1]. Patients with severe HLH exhibit dramatically elevated levels of cytokines including interleukin (IL)-1, IL-2, IL-6, IL-18, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ [2]. HLH is classified into two groups: familial and acquired. Primary HLH primarily developed as a consequence of genetic defects during infancy. Acquired HLH occurs in the context of auto-inflammatory/autoimmune diseases, lymphoma, or certain viral infections, with Epstein-Barr virus (EBV) being a common cause. Animal studies [3, 4] and case series have demonstrated that a reduction in blood cytokine levels achieved via hemoadsorption can be effective for the treatment of HLH [5, 6]. HA330-II perfusion columns have been reported to be able to absorb multiple inflammatory factors and have been successfully used as a component of a double plasma molecular adsorption system (DPMAS) to treat patients suffering from liver failure [7, 8]. In the present article, we describe one case of a children diagnosed with EBV-associated HLH combined with liver failure who successfully underwent HA330-II column hemoadsorption and chemotherapy treatment. Through these treatments, the patient’s condition ultimately improved and their recovery was satisfactory.